消息面上，帝国科技集团公布，配售最多7464.85万股新股，配售价0.845港元，较10月2日收市价折让 19.52%，配售事项所得净额6235万港元，拟将用于直接及/或间接投资于开发人工智能技术，以支援集 团的现有业务；潜在直接或间接投资于已识别的商业应用AI解决方案提供商，包括生物科技；用于集 团的一般营运资金及一般企业用途。 格隆汇10月6日｜帝国科技集团(0776.HK)今日盘中一度大涨49.1%至2.49港元，股价创今年3月6日以来 约7个月新高；该股近两个交易日股价实现翻倍。 来源：格隆汇APP ...

消息面上，帝国科技集团上周五公布，配售最多7464.85万股新股，配售价0.845港元，较10月2日收市价 折让19.52%，配售事项所得净额6235万港元，拟将用于直接及/或间接投资于开发人工智能技术，以支 援集团的现有业务；潜在直接或间接投资于已识别的商业应用AI解决方案提供商，包括生物科技；用 于集团的一般营运资金及一般企业用途。 智通财经APP获悉，帝国科技集团(00776)再涨近50%，近两日股价实现翻倍。截至发稿，涨35.33%，报 2.26港元，成交额1225.97万港元。 ...

Group 1 - Empire Technology Group (00776) experienced a significant stock price increase, initially rising nearly 64% before settling at a 46.67% increase, trading at HKD 1.54 with a transaction volume of HKD 14.6681 million [1] - The company announced a placement of up to 74.6485 million new shares, representing a 16.67% increase in the enlarged share capital, with a placement price of HKD 0.845, reflecting a 19.52% discount compared to the closing price on October 2 [1] - The total fundraising amount is HKD 63.08 million, with a net amount of HKD 62.35 million intended for direct and/or indirect investments in the development of artificial intelligence technology to support the company's existing business [1] Group 2 - The funds raised will also be used for potential direct or indirect investments in identified commercial application AI solution providers, including biotechnology [1] - Additionally, the capital will be allocated for the company's general operating funds and general corporate purposes [1]

Core Viewpoint - Empire Technology Group (00776) plans to issue up to 74.6485 million shares at a price of HKD 0.845 per share, representing a discount of approximately 19.52% from the closing price of HKD 1.050 on October 2, 2025 [1] Fundraising Details - The estimated total gross proceeds from the share placement will be approximately HKD 63.08 million, with net proceeds expected to be around HKD 62.35 million [1] - The share placement will increase the company's issued share capital by about 16.67% [1] Use of Proceeds - Approximately 48.67% of the net proceeds will be allocated to direct and/or indirect investments in the development of artificial intelligence (AI) technology to support the company's existing business [1] - About 35.29% of the net proceeds will be used for potential direct or indirect investments in identified commercial AI solution providers, including biotechnology [1] - Approximately 16.04% of the net proceeds will be allocated for general working capital and corporate purposes [1]